Payment overview · 2025
General Payments
$587.67
28 reported records · 15 companies
Healthcare provider profile · identity verified
David M Hayes, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · EVANSVILLE, IN · NPI 1295725943
Verified facts
What the public records show
CMS Open Payments records show David M Hayes, M.D. received $587.67 in general payments during 2025 across 28 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 42.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 477 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $249.62 | 42.5% | 10 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $69.26 | 11.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.98 | 8.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.90 | 5.9% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $23.55 | 4.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.28 | 3.8% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.26 | 3.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $19.06 | 3.2% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.91 | 3.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.63 | 2.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.59 | 2.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.22 | 2.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.15 | 2.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.55 | 2.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6.71 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $587.67 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $249.62 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $69.26 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $47.98 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $47.98 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.90 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.15 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.55 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $6.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 43 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 167 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 58 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
101 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
167 | 34 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
43 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
477 | 62 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1273 | 202 |
| Levothyroxine Sodium | Levothyroxine Sodium | 885 | 147 |
| Gabapentin | Gabapentin | 780 | 127 |
| Amlodipine Besylate | Amlodipine Besylate | 733 | 159 |
| Omeprazole | Omeprazole | 728 | 146 |
| Furosemide | Furosemide | 597 | 122 |
| Metoprolol Succinate | Metoprolol Succinate | 544 | 110 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 497 | 61 |
| Eliquis | Apixaban | 477 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 471 | 95 |
| Losartan Potassium | Losartan Potassium | 427 | 97 |
| Potassium Chloride | Potassium Chloride | 412 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 359 | 72 |
| Sertraline Hcl | Sertraline Hcl | 358 | 74 |
| Lisinopril | Lisinopril | 353 | 81 |
| Metformin Hcl | Metformin Hcl | 347 | 76 |
| Trazodone Hcl | Trazodone Hcl | 308 | 57 |
| Simvastatin | Simvastatin | 294 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 282 | 67 |
| Escitalopram Oxalate | Escitalopram Oxalate | 274 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 257 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 251 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 249 | 48 |
| Gemtesa | Vibegron | 232 | 19 |
| Metformin Hcl Er | Metformin Hcl | 231 | 53 |
| Donepezil Hcl | Donepezil Hcl | 226 | 38 |
| Clonazepam | Clonazepam | 221 | 30 |
| Carvedilol | Carvedilol | 220 | 44 |
| Memantine Hcl | Memantine Hcl | 218 | 41 |
| Allopurinol | Allopurinol | 210 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 204 | 44 |
| Prednisone | Prednisone | 181 | 77 |
| Lorazepam | Lorazepam | 178 | 30 |
| Ozempic | Semaglutide | 167 | 34 |
| Famotidine | Famotidine | 159 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 154 | 57 |
| Spironolactone | Spironolactone | 151 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 146 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 145 | 23 |
| Xarelto | Rivaroxaban | 145 | 20 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 135 | 92 |
| Alprazolam | Alprazolam | 133 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 133 | 26 |
| Baclofen | Baclofen | 127 | 21 |
| Olanzapine | Olanzapine | 127 | 17 |
| Divalproex Sodium | Divalproex Sodium | 121 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 121 | 32 |
| Montelukast Sodium | Montelukast Sodium | 120 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 120 | 44 |
| Finasteride | Finasteride | 119 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 118 | 22 |
| Tradjenta | Linagliptin | 115 | suppressed |
| Entresto | Sacubitril/Valsartan | 114 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 111 | 21 |
| Meloxicam | Meloxicam | 109 | 24 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 106 | 14 |
| Trulicity | Dulaglutide | 101 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 100 | 19 |
| Fluconazole | Fluconazole | 99 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 21 |
| Glimepiride | Glimepiride | 96 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 95 | 22 |
| Buspirone Hcl | Buspirone Hcl | 94 | 21 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 91 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 90 | 24 |
| Levetiracetam | Levetiracetam | 90 | 18 |
| Galantamine Hbr | Galantamine Hbr | 89 | 15 |
| Myrbetriq | Mirabegron | 89 | suppressed |
| Nystatin | Nystatin | 87 | 35 |
| Pregabalin | Pregabalin | 87 | 14 |
| Tramadol Hcl | Tramadol Hcl | 87 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 87 | 21 |
| Glipizide | Glipizide | 86 | 11 |
| Warfarin Sodium | Warfarin Sodium | 86 | 17 |
| Clonidine Hcl | Clonidine Hcl | 83 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 83 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | 22 |
| Amiodarone Hcl | Amiodarone Hcl | 79 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 24 |
| Insulin Lispro | Insulin Lispro | 78 | 27 |
| Atenolol | Atenolol | 76 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 76 | 13 |
| Jardiance | Empagliflozin | 76 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 76 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 17 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 73 | 26 |
| Ondansetron Odt | Ondansetron | 73 | 29 |
| Divalproex Sodium Er | Divalproex Sodium | 72 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 70 | 26 |
| Ibuprofen | Ibuprofen | 69 | 13 |
| Rivastigmine | Rivastigmine Tartrate | 68 | 11 |
| Ezetimibe | Ezetimibe | 67 | 11 |
| Propranolol Hcl | Propranolol Hcl | 67 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 64 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 63 | 15 |
| Diazepam | Diazepam | 61 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 60 | 37 |
| Dicyclomine Hcl | Dicyclomine Hcl | 59 | 15 |
| Estradiol | Estradiol | 58 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 55 | suppressed |
| Bupropion Xl | Bupropion Hcl | 54 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 28 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 52 | 14 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 52 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 35 |
| Linzess | Linaclotide | 50 | 11 |
| Meclizine Hcl | Meclizine Hcl | 50 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 49 | suppressed |
| Mirtazapine | Mirtazapine | 49 | 14 |
| Promethazine Hcl | Promethazine Hcl | 49 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 27 |
| Fenofibrate | Fenofibrate | 47 | suppressed |
| Amoxicillin | Amoxicillin | 46 | 31 |
| Lamotrigine | Lamotrigine | 46 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | suppressed |
| Azithromycin | Azithromycin | 45 | 17 |
| Midodrine Hcl | Midodrine Hcl | 45 | suppressed |
| Topiramate | Topiramate | 45 | suppressed |
| Valsartan | Valsartan | 45 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 43 | 42 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 42 | suppressed |
| Novolog | Insulin Aspart | 41 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 39 | suppressed |
| Amantadine | Amantadine Hcl | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 23 |
| Nitroglycerin | Nitroglycerin | 38 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 13 |
| Glipizide Er | Glipizide | 36 | suppressed |
| Latanoprost | Latanoprost | 36 | suppressed |
| Levofloxacin | Levofloxacin | 36 | 18 |
| Methotrexate | Methotrexate Sodium | 36 | suppressed |
| Bumetanide | Bumetanide | 35 | suppressed |
| Aripiprazole | Aripiprazole | 34 | 11 |
| Desmopressin Acetate | Desmopressin Acetate | 34 | suppressed |
| Sucralfate | Sucralfate | 34 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 33 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Risperidone | Risperidone | 33 | suppressed |
| Anastrozole | Anastrozole | 32 | suppressed |
| Mupirocin | Mupirocin | 32 | 22 |
| Primidone | Primidone | 32 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 31 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 30 | 17 |
| Insulin Aspart | Insulin Aspart | 30 | 11 |
| Loperamide | Loperamide Hcl | 30 | 18 |
| Prazosin Hcl | Prazosin Hcl | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 29 | suppressed |
| Colchicine | Colchicine | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 29 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 29 | suppressed |
| Admelog | Insulin Lispro | 28 | suppressed |
| Calcitriol | Calcitriol | 28 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Budesonide | Budesonide | 27 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Lidocaine | Lidocaine | 27 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 27 | 27 |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 26 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 24 | 13 |
| Clozapine | Clozapine | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 23 | suppressed |
| Novolin R | Insulin Regular, Human | 23 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Oxycontin | Oxycodone Hcl | 22 | suppressed |
| Sulfasalazine | Sulfasalazine | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 12 |
| Movantik | Naloxegol Oxalate | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | suppressed |
| Dapsone | Dapsone | 20 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 20 | 12 |
| Lactulose | Lactulose | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 19 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 13 |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Xifaxan | Rifaximin | 17 | suppressed |
| Yuvafem | Estradiol | 17 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 16 | 11 |
| Lithium Carbonate | Lithium Carbonate | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Relistor | Methylnaltrexone Bromide | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Ertapenem | Ertapenem Sodium | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Glucagon Emergency Kit | Glucagon | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Tobramycin | Tobramycin | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $587.67 · 28 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABRYSVO, AIRSUPRA, AUSTEDO XR, CAPLYTA, COMIRNATY, Cologuard Collection Kit, FANAPT, Fluad, Flucelvax, NUZYRA, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error